(Q40501431)

21 September 2017

title

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial (English)

1 reference

21 September 2017

main subject

phase I clinical trial

0 references

Shigella sonnei

object named as

Shigella sonnei

1 reference

McKenzie R

1

1 reference

21 September 2017

Walker RI

2

1 reference

21 September 2017

Nabors GS

3

1 reference

21 September 2017

Van De Verg LL

4

1 reference

21 September 2017

Carpenter C

5

1 reference

21 September 2017

Gomes G

6

1 reference

21 September 2017

Forbes E

7

1 reference

21 September 2017

Tian JH

8

1 reference

21 September 2017

Yang HH

9

1 reference

21 September 2017

Pace JL

10

1 reference

21 September 2017

Jackson WJ

11

1 reference

21 September 2017

Bourgeois AL

12

1 reference

21 September 2017

language of work or name

English

0 references

publication date

21 July 2005

1 reference

21 September 2017

1 reference

21 September 2017

volume

24

1 reference

21 September 2017

issue

18

1 reference

21 September 2017

page(s)

3735-3745

1 reference

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Immunity in Shigellosis. I. Response of Man to Attenuated Strains of Shigella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Age-Specific Prevalence of Serum Antibodies to the Invasion Plasmid and Lipopolysaccharide Antigens of Shigella Species in Chilean and North American Populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Molecular cloning of invasion plasmid antigen (ipa) genes from Shigella flexneri: analysis of ipa gene products and genetic mapping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

7 January 2021

Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

7 January 2021

Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

7 January 2021

Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

7 January 2021

Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

7 January 2021

Protection of Monkeys Against Experimental Shigellosis with Attenuated Vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.07.014

7 January 2021

10.1016/J.VACCINE.2005.07.014

Identifiers

DOI

1 reference

21 September 2017

1 reference